These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. New markers to predict the response to omalizumab in chronic spontaneous urticaria. Coşansu NC; Kara RÖ; Yaldiz M; Dikicier BS Dermatol Ther; 2022 Aug; 35(8):e15589. PubMed ID: 35582853 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria. Yuan W; Hu S; Li M; Yang L; Liu L; Zheng M; Guo Z; Song Z; Zhang C; Diao Q; Xu J; Richard A; Patwardhan M; Lyu T; Uddin A; Fogel R; Ligueros-Saylan M; Zheng J Dermatol Ther; 2022 Apr; 35(4):e15303. PubMed ID: 34984792 [TBL] [Abstract][Full Text] [Related]
9. Anti-TPO IgG/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria. Brás R; Esteves Caldeira L; Bernardino A; Costa C Int Arch Allergy Immunol; 2023; 184(9):866-869. PubMed ID: 37557083 [TBL] [Abstract][Full Text] [Related]
10. Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems. Sánchez J; Alvarez L; López JF Actas Dermosifiliogr; 2024 Jan; 115(1):88-90. PubMed ID: 36754254 [No Abstract] [Full Text] [Related]
11. Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems. Sánchez J; Alvarez L; López JF Actas Dermosifiliogr; 2024 Jan; 115(1):T88-T90. PubMed ID: 37871896 [No Abstract] [Full Text] [Related]
13. Delayed Pressure Urticaria: Clinical and Diagnostic Features and Response to Omalizumab. Veleiro-Pérez B; Alba-Muñoz J; Pérez-Quintero O; Rodríguez RL; Calvín-Lamas M; Parra-Arrondo A Int Arch Allergy Immunol; 2022; 183(10):1089-1094. PubMed ID: 35609554 [TBL] [Abstract][Full Text] [Related]
14. Clinical variables of severe chronic spontaneous urticaria from total IgE standpoint: a retrospective study. Asero R Eur Ann Allergy Clin Immunol; 2022 Jan; 54(1):30-33. PubMed ID: 33555151 [No Abstract] [Full Text] [Related]
15. Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria. Pedersen NH; Sørensen JA; Ghazanfar MN; Zhang DG; Vestergaard C; Thomsen SF Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511088 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the Patients with Chronic Urticaria Who Responded and Did Not Respond to Omalizumab Treatment: A Single-Center Retrospective Study. Cakmak ME Int Arch Allergy Immunol; 2022; 183(11):1209-1215. PubMed ID: 36007494 [TBL] [Abstract][Full Text] [Related]
18. Chronic spontaneous urticaria treated with omalizumab: what differentiates early from late responders? Asero R Eur Ann Allergy Clin Immunol; 2021 Jan; 53(1):47-48. PubMed ID: 32378398 [No Abstract] [Full Text] [Related]
19. Does synthetic pharmacotherapy still have a place in treating chronic spontaneous urticaria? Thiede RM; Fazel M; MacDonald KM; Abraham I Expert Opin Pharmacother; 2022 Oct; 23(14):1563-1567. PubMed ID: 36173375 [No Abstract] [Full Text] [Related]
20. Drugs in Development for Chronic Spontaneous Urticaria. Nguyen W; Liu W; Yamauchi P J Drugs Dermatol; 2023 Apr; 22(4):393-397. PubMed ID: 37026883 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]